Amiante et maladies respiratoires Paul De Vuyst Hopital Erasme ULB, - - PowerPoint PPT Presentation

amiante et maladies respiratoires
SMART_READER_LITE
LIVE PREVIEW

Amiante et maladies respiratoires Paul De Vuyst Hopital Erasme ULB, - - PowerPoint PPT Presentation

Amiante et maladies respiratoires Paul De Vuyst Hopital Erasme ULB, Bruxelles Asbestos exposure Occupational : salaried or self-standing (independent) workers . Para-occupational : households of asbestos workers (wives, children)


slide-1
SLIDE 1

Amiante et maladies respiratoires

Paul De Vuyst Hopital Erasme ULB, Bruxelles

slide-2
SLIDE 2

Asbestos exposure

  • Occupational : salaried or self-standing (independent)

workers .

  • Para-occupational : households of asbestos workers (wives,

children)

  • Environmental

– naturally occurring asbestos (Turkey, Corsica …) – neighbourhood of asbestos mines or factories – indoor “passive” exposure in buildings

  • Mixed environmental and para-occupational
slide-3
SLIDE 3

Evolution of occupational exposure

  • Shift from traditional occupations handling raw

asbestos to end-users, especially in the construction industry

  • Most currently exposed workers are in contact

with asbestos material still in place: heating workers, electricians, plumbers, demolition workers, asbestos removers...

  • These workers are often self-standing

workers or even undeclared workers

slide-4
SLIDE 4

Asbestos exposure

  • Occupational : salaried or self-standing workers
  • Para-occupational : households of asbestos

workers (wives, children)

  • Environmental

– Naturally occurring asbestos (Turkey, Corsica …) – Neighborhood of asbestos mines or factories – Mixed environmental and para-occupational

slide-5
SLIDE 5

Asbestos exposure

  • Occupational : salaried or self-standing workers
  • Para-occupational : households of asbestos

workers (wives, children)

  • Environmental

– Naturally occurring asbestos (Turkey, Corsica …) – Neighborhood of asbestos mines or factories – Mixed environmental and para-occupational

slide-6
SLIDE 6

"Environmental" exposures to tremolite

  • Domestic use of asbestos deposits (house whitewashing)

and farming on contaminated soils

  • Exposure starts at birth and lasts

24 hour/day

  • Lung fiber counts indicate

cumulative exposures similar to occupational settings

Dumortier P et al, Am J Respir Crit Care Med 1998; 158: 1815-1824

slide-7
SLIDE 7

Environmental (“imported”) asbestosis

  • Man, born in Turkey (Malatya)

in 1930

  • Migrated to Belgium

in 1974 (no occupational exposure to asbestos)

  • BAL

– LM : 1530 AB/ml – EM : TREMOLITE 100 %

slide-8
SLIDE 8

Asbestos exposure

  • Occupational : salaried or self-standing workers
  • Para-occupational : households of asbestos

workers (wives, children)

  • Environmental

– Naturally occurring asbestos (Turkey, Corsica …) – Neighborhood of asbestos mines or factories – Mixed environmental and para-occupational

slide-9
SLIDE 9

Asbestos exposure

  • Occupational : salaried or self-standing workers
  • Para-occupational : households of asbestos

workers (wives, children)

  • Environmental

– Naturally occurring asbestos (Turkey, Corsica …) – Neighborhood of asbestos mines or factories – Mixed environmental and para-occupational

slide-10
SLIDE 10

Respiratory disorders induced by asbestos

  • Asbestosis (lung fibrosis)
  • Non-malignant pleural lesions

Pleural plaques Diffuse pleural thickening (DPT) Benign asbestos pleural effusion (BAPE)

  • Malignant Mesothelioma
  • Lung Cancer
slide-11
SLIDE 11

Specific respiratory disorders induced by asbestos

  • Asbestosis (lung fibrosis)
  • Non-malignant pleural lesions

Pleural plaques Diffuse pleural thickening (DPT) Benign asbestos pleural effusion (BAPE)

  • Malignant Mesothelioma
  • Lung Cancer
slide-12
SLIDE 12

Specific respiratory disorders induced by asbestos

  • Asbestosis (lung fibrosis)
  • Non-malignant pleural lesions

Pleural plaques Diffuse pleural thickening (DPT) Benign asbestos pleural effusion (BAPE)

  • Malignant Mesothelioma
  • Lung Cancer
slide-13
SLIDE 13

Pleural plaques

  • Most frequent manifestation of asbestos exposure : marker of

exposure rather than disease

  • Circumscribed areas of fibrosis of the parietal pleura, which

may calcify

  • Located on the thoracic wall and on the central parts of the

diaphragm

  • Covered with normal mesothelium, without adherences

(normal lung movements)

  • No detectable effect on lung volumes in individuals, unless

very extensive

slide-14
SLIDE 14

Specific respiratory disorders induced by asbestos

  • Asbestosis (lung fibrosis)
  • Non-malignant pleural lesions

Pleural plaques Diffuse pleural thickening (DPT) Benign asbestos pleural effusion (BAPE)

  • Malignant Mesothelioma
  • Lung Cancer
slide-15
SLIDE 15
slide-16
SLIDE 16

Mesothelioma and Asbestos

  • Amosite and crocidolite have a higher carcinogenic

potency than chrysotile: more biopersistent in the lungs

  • Historical exposures involved generally a mixture of

fiber types

  • The mean latency is at least 40 years since first

exposure → the age at onset of exposure is crucial

  • A threshold of cumulative exposure below which

there is no increased risk cannot be defined: low-dose cumulative exposures can cause MM

slide-17
SLIDE 17

Black spots on the parietal pleura

  • Deposition of exogenous inhaled particles is

heterogeneous in the parietal pleura and occur in "hot spots" ("black spots")

  • Present in virtually all urban dwellers
  • Contain macrophages and lymphocytes
  • Colour is due to carbonaceous pigments and soot

deposits, which indicate the presence of exogenous (inhaled) material

slide-18
SLIDE 18

Epidemiology

  • Background incidence : ± 1/106
  • Industrialized countries (Europe): 15 - 30/106
  • Great differences in incidences reported from

countries worldwide

  • Differences mainly due to historical asbestos

import and consumption (amounts and types)

slide-19
SLIDE 19

Screening

  • A screening is justified if the early detection of the

disease improves the prognosis by more effective medical or surgical treatment and if there are performant screening methods

  • To date, according to the prevalence, prognosis,

available treatments of MPM and to the performance of potential screening methods, the medical efficacy of a large-scale screening is not established

slide-20
SLIDE 20

Screening

  • Low dose CT has not been proven to be an effective

screening tool for the detection of (early) MPM

  • PET and MRI are not available and/or applicable for

screening purposes

  • No evidence that early discovery of MPM will cure the

patient or even improve his survival

slide-21
SLIDE 21

Belgian study on SMRP and MPF

  • Soluble Mesothelin Related Peptide
  • Megakaryocyte Potentiating Factor
  • « Normal » values or « cut-off » values : 2 nM/ml and 14 mg/ml

(specificity 95 % and sensitivity 65 %)

slide-22
SLIDE 22

2 nM/ml 14 mg/ml

slide-23
SLIDE 23

Simulation of screening (France)

  • Mesothelin: Se 80% and Sp 95%
  • Incidence of MPM: 100 per million (all) exposed subjects
  • Target population 6 million exposed workers
  • → 600 expected MPM
  • True positive cases 480 (600 x 0.8)
  • False negative cases 120 (600 x 0.2)
  • False positive cases 300000 (6.10 6 x 0.05)
  • If test positive: less than 2/1000 « chances » to have

mesothelioma

(Courtesy of Bruno Housset)

slide-24
SLIDE 24

Requirements for recognition (ODF)

  • Occupational exposure risk confirmed by

an occupational enquiry (occupational engineers)

  • Only for wage-earners (salaried workers).

No compensation for self-employed (independent) workers

slide-25
SLIDE 25

The Belgian Asbestos Fund (AFA)

  • Political decision under “social pressure”

( France, ANDEVA and FIVA)

  • ABEVA (Association belge des victimes de l’amiante)
  • Cases of mesothelioma and neighbourhood or para-
  • ccupational exposures
  • The Asbestos Fund

– Act of December 27th, 2006 – Effective creation on April 1st, 2007

  • Organized within the ODF (FMP/FBZ)
slide-26
SLIDE 26

Amiante : une “carrière” de 35 ans (1979 – 2014).

  • Jean Claude Yernault (Pneumologue)
  • Jacques Jedwab et Pascal Dumortier (Minéralogistes)
  • Pierre Alain Gevenois (Radiologue)
  • Myriam Remmelink (Anatomo-pathologiste)
  • Raymond Vande Weyer et Joël Thimpont (FMP)
  • Françoise Rey et Christian Boutin (Marseille et Corse)
  • Jean Bignon (Paris)
  • Izzet Baris (Ankara)
  • Chris Wagner et Allen Gibbs (Cardiff)
slide-27
SLIDE 27